Nov 27, 2022
Provention Bio Inc has priced its diabetes drug teplizumab at $13,850 a vial, it said on Friday, a day after receiving U.S. approval and far higher than some analysts' expectations.
seen from Switzerland
seen from United Kingdom
seen from South Korea
seen from Türkiye
seen from China
seen from United States
seen from Kazakhstan
seen from Switzerland
seen from China
seen from Japan
seen from United States
seen from China
seen from United Kingdom
seen from Poland
seen from Russia
seen from United States
seen from Poland
seen from United States
seen from China
seen from China
Provention Bio Inc has priced its diabetes drug teplizumab at $13,850 a vial, it said on Friday, a day after receiving U.S. approval and far higher than some analysts' expectations.
Provention Bio sets terms for $50 million best-efforts IPO Provention Bio which is developing novel therapies for autoimmune and inflammatory diseases announced terms for its IPO on Wednesday The deal is being conducted on a best efforts basis and is therefore excluded from Renaissance Capital s IPO stats The Oldwick NJ based company plans... Latest Articles in
You have been given this life because you are strong enough to live it.